DNMT3A and rheumatoid arthritis: Similarly, rheumatoid arthritis (RA) patients have a 17% higher prevalence of CHIP, which increases to 25% in individuals aged 70-79 years, with DNMT3A and TET2 mutations being the most frequent (99).